COMPARISON OF FLUORINE-18-2-FLUORODEOXYGLUCOSE AND GA-67-CITRATE IMAGING FOR DETECTION OF LYMPHOMA

Google Scholar
  • 1 March 1987
    • journal article
    • research article
    • Vol. 28  (3) , 288-292
Abstract
Patients with lymphomas are conventionally imaged with [67Ga]citrate for tumor detection and determination of dissemination. Fluorine-18-2-fluoro-2-deoxy-D-glucose ([18F]FDG) is a radiopharmaceutical that accumulates into tissues where glucose utilization is enhanced, such as tumors. Six cancer patients (five non-Hodgkin''s lymphomas, one endodermal retroperitoneal sinus carcinoma) were imaged with [18F]FDG and [67Ga]citrate whole-body scintigraphies in order to compare the sensitivities of these two tumor imaging radiopharmaceuticals. Among the five untreated lymphoma patients, two 67Ga scans and four [18F]FDG scans were positive; in the patient with the retroperitoneal carcinoma who had a positive [18F]FDG scan before treatment, both scans were negative after treatment. Fluorine-18 FDG may be a more sensitive tumor-detecting radiopharmaceutical for non-Hodgkin''s lymphoma than [67Ca]citrate.

This publication has 1 reference indexed in Scilit: